These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25820099)

  • 1. Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.
    Wilson JN; Liu W; Brown AS; Landgraf R
    Org Biomol Chem; 2015 May; 13(17):5006-11. PubMed ID: 25820099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and photophysical properties of a fluorescent cyanoquinoline probe for profiling ERBB2 kinase inhibitor response.
    Lee H; Landgraf R; Wilson JN
    Bioorg Med Chem; 2017 Nov; 25(21):6016-6023. PubMed ID: 28974323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects.
    Dhuguru J; Liu W; Gonzalez WG; Babinchak WM; Miksovska J; Landgraf R; Wilson JN
    J Org Chem; 2014 Jun; 79(11):4940-7. PubMed ID: 24784897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
    Petrov KG; Zhang YM; Carter M; Cockerill GS; Dickerson S; Gauthier CA; Guo Y; Mook RA; Rusnak DW; Walker AL; Wood ER; Lackey KE
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4686-91. PubMed ID: 16777410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
    Huang Y; Rizzo RC
    Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescent Kinase Probes Enabling Identification and Dynamic Imaging of HER2(+) Cells.
    Lee H; Liu W; Brown AS; Landgraf R; Wilson JN
    Anal Chem; 2016 Dec; 88(23):11310-11313. PubMed ID: 27934102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
    Benter IF; Sarkhou F; Al-Khaldi AT; Chandrasekhar B; Attur S; Dhaunsi GS; Yousif MH; Akhtar S
    J Drug Target; 2015; 23(6):506-18. PubMed ID: 26114862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
    Li J; Lin B; Li X; Tang X; He Z; Zhou K
    Oncol Rep; 2015 Feb; 33(2):951-7. PubMed ID: 25482142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
    Lackey KE
    Curr Top Med Chem; 2006; 6(5):435-60. PubMed ID: 16719802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
    Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
    Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
    Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
    J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
    Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
    Chen S; Li X; Feng J; Chang Y; Wang Z; Wen A
    Med Hypotheses; 2011 Aug; 77(2):206-8. PubMed ID: 21570197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib and breast cancer: current indications and outlook for the future.
    Moreira C; Kaklamani V
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1171-82. PubMed ID: 20735304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.